中国实用内科杂志2017，Vol.37Issue(9)：790-793,4.DOI:10.19538/jnk2017090104
C3肾小球病治疗进展
Advances in the treatment of C3 glomerulopathy
陈楠1
作者信息
- 1. 上海交通大学医学院附属瑞金医院肾脏科上海交通大学医学院附属肾脏病研究所,上海200025
- 折叠
摘要
Abstract
C3 glomerulonephropathyincludes C3 glomerulonephritis and dense deposit disease,which has a variety of clinical manifestations and its diagnosis depends on renal biopsy.There is no uniform treatment guideline,and it is recommended treatment should be according to the etiology of C3 glomerulonephropathy,by controlling the overactivation of the complement alternative pathway.Nephrotic syndrome with/without renal insufficiency inpatients is recommended to be managed by active treatment,and.Treatment options include steroids combined with immunosuppressive agents;biological agents anti-CD20 monoclonal antibody-Rituximab is effective in a small number of patients;howerver,anti-C5 monoclonal antibody-Eculizumab which is not listed in China,is effective in most patients;plasma exchange/frozen plasma infusion has a certain effect;kidney transplant is advisible,but the recurrence rate is high.关键词
C3肾小球病/补体旁路途径/EculizumabKey words
C3 glomerulonephropathy/complement alternative pathway/Eculizumab分类
医药卫生引用本文复制引用
陈楠..C3肾小球病治疗进展[J].中国实用内科杂志,2017,37(9):790-793,4.
